Featured Research

from universities, journals, and other organizations

Botulinum toxin does not cure common forms of neck pain

Date:
July 6, 2011
Source:
Wiley-Blackwell
Summary:
There is no evidence that Botulinum toxin injections reduce chronic neck pain or associated headaches, says a group of scientists who reviewed nine trials involving a total of 503 participants.

There is no evidence that Botulinum toxin injections reduce chronic neck pain or associated headaches, says a group of scientists who reviewed nine trials involving a total of 503 participants. Their findings are published in the latest update of The Cochrane Library.

The Botulinum toxin (BoNT) operates by temporarily stopping muscles contracting. This reduces muscle tightness or spasm. It is best known for its use in cosmetic treatments where commercially available products such as Botox, Dysport, Xeomin, Myobloc or Neurobloc are used to reduce wrinkles. Effects begin within three to eight days of an injection and may last up to four months. When the effect wears off, it can be repeated.

Having an injection of a very small volume of BoNT is not risk free, and patients may experience muscle tenderness or pain, weakness, or a general sense of being unwell. A few have anaphylactic reactions and there are reports that some have died.

"It's always important to look carefully at evidence from clinical trials to see whether a treatment is more effective than a placebo, and this is particularly important when treatments have known adverse effects," says the study's spokesperson, Dr Paul Michael Peloso, who works as a director of clinical research at Merck, in New Jersey, USA.

Some of the trials specifically compared the effects of either giving the toxin or a placebo injection of saline to two different groups of people with neck pain. The researchers could see no difference between the two groups either at 4 weeks or 6 months. Similarly adding BoNT to physiotherapy was no more effective than adding either an anaesthetic or saline.

"It is possible that BoNT did give some benefits that were not measured in the trials, or that it could help highly particular types of neck pain, but we would need some much more carefully conducted trials to reveal this," says Peloso.

"Based on current evidence we have no reason for supporting the use of BoNT as a stand-alone therapy for neck pain, but we do suggest that researchers consider further study to clarify whether the dose can be optimized for neck pain" says Peloso. The researchers also believe that trials should be run that look at other symptoms than pain, such as function, to see if there is any reason for believing that BoNT can provide some benefit.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Botulinum toxin does not cure common forms of neck pain." ScienceDaily. ScienceDaily, 6 July 2011. <www.sciencedaily.com/releases/2011/07/110705211016.htm>.
Wiley-Blackwell. (2011, July 6). Botulinum toxin does not cure common forms of neck pain. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/07/110705211016.htm
Wiley-Blackwell. "Botulinum toxin does not cure common forms of neck pain." ScienceDaily. www.sciencedaily.com/releases/2011/07/110705211016.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins